(REH-tih-FAN-lih-mab)
Retifanlimab-dlwr is a type of drug called an immune checkpoint inhibitor. It works by binding to the protein PD-1 on the surface of certain immune cells called T cells, which keeps cancer cells from suppressing the immune system. This allows the immune system to attack the cancer cells.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Retifanlimab-dlwr is approved to treat adults with:
- Merkel cell carcinoma (a type of skin cancer) that has spread or has come back.
Retifanlimab-dlwr is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit in these patients.
Retifanlimab-dlwr is also being studied in the treatment of other types of cancer.
More About Retifanlimab-dlwr
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Retifanlimab-dlwr – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Retifanlimab-dlwr – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
